RB1-NEGATIVE

Clinical trials for RB1-NEGATIVE explained in plain language.

Never miss a new study

Get alerted when new RB1-NEGATIVE trials appear

Sign up with your email to follow new studies for RB1-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill takes aim at Hard-to-Treat sarcoma

Disease control Not yet recruiting

This early-phase trial tests a new oral drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread and no longer responds to standard treatments. The drug targets a protein called CDK7, which may help control tumor growth. The main goal is to ch…

Matched conditions: RB1-NEGATIVE

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 23, 2026 11:58 UTC

RB1-NEGATIVE

Get alerted when new RB1-NEGATIVE trials appear

New pill takes aim at Hard-to-Treat sarcoma